What is Replimune Group Inc (REPL) stock price today?

Replimune Group Inc (REPL) currently trades at $2.38 per share. The stock has a market capitalization of $212.21M and a P/E ratio of —x.

Is REPL stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Replimune Group Inc has a Smart Value Score of 29/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -1.18.

Is Replimune Group Inc financially healthy?

Replimune Group Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -1.18 places it in the distress.

REPL

Replimune Group Inc

NASDAQ: REPL · HEALTHCARE · BIOTECHNOLOGY

$2.38

-7.39% today

Updated 2026-04-29

Market cap

$212.21M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.44

Dividend yield

—

52W range

$2 – $13

Volume

5.4M

Market cap

$212.21M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.44

Dividend yield

—

52W range

$2 – $13

Volume

5.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-1.2

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$3.50

+47.06%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy5 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.37x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -1.18 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-66.09M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-118.04M	$-174.28M	$-215.79M	$-247.30M	$-70.93M
EPS	—	—	—	—	$-3.44
Free cash flow	$-84.52M	$-130.32M	$-191.13M	$-198.94M	$-66.09M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
REPL	$212.21M	29	4.3	3.0	5.0	5.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Replimune Group Inc trades at $2.38. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -1.18, it sits in the distress.

Frequently asked questions

What is Replimune Group Inc's stock price?

Replimune Group Inc (REPL) trades at $2.38.

Is Replimune Group Inc overvalued?

Smart Value Score 29/100 (Grade F, Strong Sell).

What is the price target of Replimune Group Inc (REPL)?

The analyst target price is $3.50, representing +47.1% upside from the current price of $2.38.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-1.18 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-90.90%

Beta0.74

50D MA$6.22

200D MA$7.08

Shares out0.08B

Float0.06B

Short ratio—

Avg volume5.4M

Performance

1 week-43.40%

1 month-33.33%

3 months-40.72%

YTD-51.03%

1 year—

3 years—

5 years—

Compare

REPL vs LLY →REPL vs JNJ →REPL vs ABBV →Stock screener →